Adaptive Biotechnologies (ADPT) Cost of Revenue (2018 - 2026)

Adaptive Biotechnologies has disclosed Cost of Revenue across 9 years of filings, most recently posting $18.7 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $18.7 million, up 10.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $73.1 million (down 7.97% YoY), and the FY2025 annual result was $71.4 million, down 15.81% from the prior year.
• Cost of Revenue came in at $18.7 million for Q1 2026 at Adaptive Biotechnologies, up from $18.2 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $26.1 million in Q1 2022 to a low of $8.9 million in Q4 2023.
• The 5-year median for Cost of Revenue is $18.7 million (2026), against an average of $19.2 million.
• Across the five-year window, Cost of Revenue slumped 62.56% in 2023 and soared 142.96% in 2024, its largest moves.
• Adaptive Biotechnologies' Cost of Revenue stood at $23.7 million in 2022, then slumped by 62.56% to $8.9 million in 2023, then jumped by 142.96% to $21.6 million in 2024, then dropped by 15.53% to $18.2 million in 2025, then grew by 2.66% to $18.7 million in 2026.
• The last three Cost of Revenue figures came in at $18.7 million (Q1 2026), $18.2 million (Q4 2025), and $18.2 million (Q3 2025), per Business Quant data.